Both in vitro studies and xenograft animal models employing various human tumor cell lines have demonstrated the therapeutic promise of geldanamycin (38) in cancer treatment, particularly in solid cancer types, not only due to potent cytotoxicity but also due to a significant decrease in cell invasion deriving from HIF-1α-mediated effects [224,225,226,227]. This evidence concerns the gene HIF1A and neoplasm.